Formosa Journal of Multidisciplinary Research (FJMR)
Vol. 5 No. 7, 2026: 1923-1938

Utilizing Artificial Intelligence to Optimize Sustainable Modern Precision Drug Development

Junius Gian Ginting
Universitas Senior Medan
Corresponding Author: Junius Gian Ginting junius06gian@gmail.com

A R T I C L E I N F O
Keywords: Artificial Intelligence, Precision Drug Development, Sustainable Pharmaceutical Innovation

Received : 20, May
Revised : 22, June
Accepted: 25, July

A B S T R A C T
Artificial Intelligence (AI) has emerged as a transformative technology in the pharmaceutical industry, offering innovative solutions to accelerate drug discovery, enhance precision medicine, and improve sustainability in healthcare systems. Conventional drug development is often characterized by lengthy timelines, high costs, and significant failure rates, creating a need for more efficient and data-driven approaches. This study aims to analyze the role of AI in optimizing sustainable modern precision drug development. The research employed a Systematic Literature Review (SLR) method following the PRISMA 2020 framework. Literature was collected from major scientific databases, including Scopus, Web of Science, PubMed, ScienceDirect, SpringerLink, IEEE Xplore, and Google Scholar. From an initial pool of 152 articles, 10 studies published between 2020 and 2025 met the inclusion criteria and were analyzed using thematic synthesis. The findings reveal that AI significantly accelerates drug discovery, supports personalized medicine through multi-omics data integration, enhances sustainability by improving resource efficiency, and drives pharmaceutical innovation through generative AI technologies. However, challenges related to data quality, transparency, ethics, and regulatory compliance remain critical barriers. Overall, AI represents a strategic enabler for sustainable, efficient, and patient-centered pharmaceutical development.

DOI: https://doi.org/10.55927/fjmr.v5i7.129
ISSN-E: 2829-8896
https://journalfjmr.my.id/index.php/fjmr

INTRODUCTION

Artificial Intelligence (AI) has emerged as a transformative technology across numerous sectors, including the pharmaceutical and healthcare industries. In recent years, AI has evolved from a data-processing tool into a strategic technology capable of supporting biological target identification, molecular drug design, toxicity prediction, and the optimization of the entire drug development process (Pushkaran & Arabi, 2024; Khan et al., 2024). The ability of AI to analyze complex and large-scale biological datasets enables pharmaceutical research to be conducted more rapidly, accurately, and efficiently than conventional approaches, which often require many years and substantial financial investment (Zhang et al., 2025; Zhang et al., 2024). Furthermore, advances in machine learning and deep learning have created new opportunities for precision medicine, allowing treatments to be tailored according to the unique characteristics of individual patients (Alowais et al., 2023; Chen et al., 2024).

Modern drug development faces numerous challenges, including high failure rates of drug candidates during clinical trials and the escalating costs of research and development (R&D). Traditionally, the drug discovery and development process requires approximately 10–15 years and billions of dollars before a new therapeutic product can reach the market (Zhang et al., 2024; Ghislat et al., 2024). The growing complexity of disease mechanisms, lengthy laboratory validation procedures, and uncertainties associated with clinical outcomes necessitate more innovative and adaptive approaches to pharmaceutical research (Khan et al., 2024; Zhang et al., 2025). In this context, AI offers promising solutions through predictive modeling capabilities that can accelerate the identification of potential compounds while reducing the likelihood of failure during later development stages (Pushkaran & Arabi, 2024; Zhang et al., 2024).

Alongside the advancement of precision medicine, the application of AI has become increasingly relevant due to its ability to integrate and analyze genomic, proteomic, metabolomic, and clinical patient data. Precision medicine emphasizes the delivery of therapies tailored to individual biological characteristics, thereby improving treatment efficacy and minimizing adverse effects (Fornasier et al., 2024; Zhang et al., 2025). AI can uncover patterns that are difficult to identify through conventional analytical methods and generate evidence-based therapeutic recommendations that support personalized healthcare strategies (Pushkaran & Arabi, 2024; Khan et al., 2024). Consequently, the integration of AI with precision medicine is increasingly recognized as a foundational component of sustainable drug development, offering both clinical effectiveness and resource efficiency.

Beyond enhancing efficiency, AI also contributes significantly to sustainability in modern pharmaceutical development. Predictive modeling and computational simulations can reduce the need for repetitive laboratory experiments, minimize animal testing, and optimize the utilization of research resources (Wang et al., 2024; Zhang et al., 2025). Moreover, generative AI technologies have demonstrated the capability to design novel molecular structures with higher probabilities of success, thereby accelerating lead

optimization and reducing research expenditures (Liu et al., 2024; Khan et al., 2024). As a result, major pharmaceutical companies worldwide are increasingly investing in AI-driven platforms to improve innovation productivity and expedite the development of new therapeutic candidates (Reuters, 2024; Reuters, 2026).

LITERATURE REVIEW

The urgency of investigating AI-based optimization strategies for sustainable precision drug development continues to increase in response to the growing demand for effective, rapid, and affordable therapies worldwide. Rising incidences of chronic diseases, rare diseases, and antimicrobial resistance require innovative solutions capable of accelerating drug discovery while maintaining safety and quality standards (The Guardian, 2024; Zhang et al., 2024). At the same time, challenges related to data quality, algorithmic bias, model transparency, ethical concerns, and regulatory compliance remain significant barriers to the broader adoption of AI within the pharmaceutical industry (Ghislat et al., 2024; Alizadehsani et al., 2023). Therefore, comprehensive investigations are needed to understand how AI can be optimally leveraged to support sustainable and precision-oriented drug development frameworks.

Several previous studies have examined the application of AI in drug discovery and development. Pushkaran and Arabi (2024) highlighted the role of AI in bridging disease understanding and drug design through data-driven methodologies. Khan et al. (2024) explored recent advancements in AI applications across multiple stages of drug discovery, including target identification and lead optimization. Fornasier et al. (2024) investigated the intersection of AI and precision medicine in enhancing individualized therapeutic outcomes. Zhang et al. (2024) discussed the contributions of AI in accelerating drug discovery, development, and clinical trial implementation. Meanwhile, Zhang et al. (2025) demonstrated that AI has become a paradigm-shifting technology throughout the pharmaceutical lifecycle. However, most existing studies focus on either technical AI applications or precision medicine independently, leaving a limited understanding of how AI, precision medicine, and sustainability can be integrated within a comprehensive drug development framework.

Based on the aforementioned background, this study aims to analyze and evaluate the role of Artificial Intelligence in optimizing sustainable modern precision drug development. Specifically, the study seeks to identify key AI technologies utilized in drug discovery and development processes, examine their contributions to precision medicine, and explore the opportunities and challenges associated with their implementation in creating more efficient, innovative, and sustainable pharmaceutical systems.

METHODOLOGY

This study employed a Systematic Literature Review (SLR) approach to identify, evaluate, and synthesize research findings related to the utilization of Artificial Intelligence (AI) in optimizing sustainable modern precision drug

development. The SLR method was selected because it provides a transparent, systematic, and reproducible procedure for reviewing scientific evidence and identifying research trends, opportunities, challenges, and future directions (Kitchenham & Charters, 2007; Snyder, 2019). The review process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, which include the stages of identification, screening, eligibility assessment, and inclusion (Page et al., 2021).

Literature searches were conducted in Scopus, Web of Science, PubMed, ScienceDirect, SpringerLink, IEEE Xplore, and Google Scholar between January and March 2026. The search strategy used Boolean operators with the following keywords: ("artificial intelligence" OR "machine learning" OR "deep learning") AND ("drug discovery" OR "drug development") AND ("precision medicine" OR "personalized medicine") AND ("sustainability" OR "sustainable healthcare"). This strategy was designed to retrieve studies specifically discussing the integration of AI in precision drug development and sustainable pharmaceutical innovation.

The article selection process was conducted systematically. The initial database search identified 152 articles. After removing 32 duplicate records, 120 articles remained for title and abstract screening. During the screening stage, 80 articles were excluded because they were not directly related to AI-based drug development, precision medicine, or sustainability. Consequently, 40 articles proceeded to the full-text eligibility assessment. In the eligibility stage, 30 articles were excluded due to insufficient methodological information, lack of full-text access, or failure to meet the inclusion criteria. Finally, 10 articles were included in the final review and synthesis. The selection process can be summarized as follows:



Figure 1. PRISMA 2020 Flow Diagram

Inclusion and Exclusion Criteria

The inclusion criteria were: (1) articles published between 2020 and 2025; (2) peer-reviewed journal articles, empirical studies, systematic reviews, or conceptual papers; (3) studies discussing AI, machine learning, deep learning, or other intelligent computational techniques in drug discovery, drug development, clinical trials, or personalized medicine; (4) availability of full-text articles; and (5) publication in English. Exclusion criteria included editorials, conference abstracts, news reports, book reviews, duplicate publications, and studies lacking sufficient methodological details.

Data Extraction and Analysis

Data extraction was performed systematically using a literature synthesis matrix containing information on authors, publication year, country, research objectives, methodology, AI techniques used, application areas in drug development, key findings, benefits, and implementation challenges. The

extracted data were analyzed using thematic synthesis (Thomas & Harden, 2008). The analysis involved open coding, categorization of similar findings, and the development of broader themes related to AI applications in target identification, molecular design, toxicity prediction, clinical trial optimization, personalized therapy, cost efficiency, and sustainability in pharmaceutical development.

Quality Assessment

To ensure the credibility of the review, the quality of the included studies was assessed using criteria adapted from the Critical Appraisal Skills Programme (CASP) and systematic review evaluation guidelines proposed by Okoli (2015). The assessment considered the clarity of research objectives, methodological rigor, data validity, transparency of analysis, and relevance to the review topic. Only studies with adequate methodological quality were included in the final synthesis.

RESEARCH RESULT

Based on the PRISMA 2020 selection process, a total of 10 articles were included in the final review. These studies were published between 2020 and 2025 and represent recent developments in the application of Artificial Intelligence (AI) within drug discovery, drug development, precision medicine, and sustainable pharmaceutical innovation. The selected articles encompass various methodological approaches, including systematic reviews, conceptual analyses, empirical studies, and technology-focused investigations. Collectively, they provide comprehensive insights into how AI contributes to accelerating drug development, improving precision medicine outcomes, reducing research costs, and supporting sustainability objectives in modern pharmaceutical systems. To facilitate comparative analysis, the characteristics and key findings of the selected studies are presented in Table 1–Table 10.

Table 1. Characteristics of Selected Studies on the Utilization of Artificial Intelligence in Sustainable Modern Precision Drug Development

No.	Authors (Year)	Research Objective	Methodology	AI Technology/ Application	Main Findings
1	Pushkaran & Arabi (2024)	To examine the role of AI across the drug discovery process.	Literature Review	AI, Machine Learning	AI improves disease understanding, target identification, and drug design.
2	Khan et al. (2024)	To review recent advances in AI-driven drug discovery.	Review Study	Machine Learning, Deep Learning	AI accelerates compound screening and lead optimization.

3	Zhang et al. (2024)	To analyze AI applications throughout the pharmaceutical lifecycle.	Narrative Review	AI Analytics, Predictive Modeling	AI supports drug discovery, development, and clinical trial optimization.
4	Fornasier et al. (2024)	To investigate the relationship between AI and precision medicine.	Review Article	AI, Multi-omics Integration	AI enables personalized therapeutic decision-making.
5	Liu et al. (2024)	To explore the application of generative AI in drug discovery.	Systematic Review	Generative AI	Generative AI creates novel molecular structures with therapeutic potential.
6	Wang et al. (2024)	To evaluate AI implementation across pharmaceutical industries.	Review Article	AI, Automation Systems	AI improves formulation development, manufacturing, and quality control.
7	Ghislat et al. (2024)	To identify challenges in AI adoption for drug discovery.	Review Study	Data-Centric AI	Data quality and interoperability remain major challenges.
8	Alizadehsani et al. (2023)	To examine explainable AI approaches in pharmaceutical research.	Comprehensive Survey	Explainable AI (XAI)	XAI increases transparency, interpretability, and trustworthiness.

9	Alowais et al. (2023)	To evaluate AI applications in healthcare and clinical practice.	Review Article	AI Clinical Decision Support	AI improves diagnosis, treatment planning, and healthcare delivery.
10	Zhang et al. (2025)	To investigate emerging AI innovations in drug development.	Review Article	AI, Deep Learning, Predictive Modeling	AI transforms all stages of pharmaceutical innovation.

Table 1 presents the characteristics of the ten studies selected through the PRISMA 2020 review process. The studies were published between 2023 and 2025 and predominantly employed review-based methodologies, reflecting the rapidly evolving nature of AI applications in pharmaceutical research. The findings reveal that Artificial Intelligence has been utilized across multiple stages of drug development, including disease understanding, target identification, molecular design, lead optimization, clinical trial management, manufacturing processes, and precision medicine implementation.

Among the selected studies, machine learning, deep learning, generative AI, predictive analytics, and explainable AI emerged as the most frequently discussed technologies. The evidence consistently indicates that AI contributes to faster drug discovery, enhanced therapeutic personalization, improved decision-making accuracy, and reduced research costs. Furthermore, several studies highlighted the role of AI in supporting sustainability through resource optimization, reduction of experimental redundancy, and increased efficiency in pharmaceutical production and clinical development.

Despite these benefits, challenges related to data quality, algorithmic transparency, interoperability, ethical concerns, and regulatory acceptance remain significant barriers to widespread implementation. Nevertheless, the collective findings suggest that the integration of AI, precision medicine, and sustainability constitutes a promising paradigm for future pharmaceutical innovation, enabling more effective, efficient, and patient-centered drug development processes.

The thematic analysis of the ten selected studies identified five major themes that characterize the contribution of Artificial Intelligence (AI) to the optimization of sustainable modern precision drug development. These themes include: (1) accelerating drug discovery and development processes, (2) strengthening precision medicine through multidimensional data integration, (3) enhancing sustainability and efficiency in pharmaceutical development, (4) transforming innovation through generative AI and advanced analytics, and (5)

addressing challenges and governance issues in AI implementation. Each theme represents recurring patterns and consistent findings across the reviewed literature.

Theme 1. Accelerating Drug Discovery and Development Processes

The first theme highlights the significant role of AI in accelerating various stages of drug discovery and development. Most of the reviewed studies reported that machine learning and deep learning algorithms are capable of identifying biological targets, predicting compound activity, and performing molecular screening more efficiently than conventional approaches (Pushkaran & Arabi, 2024; Khan et al., 2024; Zhang et al., 2024). AI enables researchers to analyze millions of molecular datasets within a relatively short period, thereby reducing the time and cost associated with laboratory-based experiments.

Furthermore, AI technologies are increasingly utilized to predict pharmacokinetic and pharmacodynamic properties before compounds enter clinical trials. These predictive capabilities help researchers minimize development risks and improve the probability of selecting successful drug candidates. The findings suggest that AI has transformed drug discovery from a traditional trial-and-error approach into a data-driven and predictive process.

Key Findings:

a. AI accelerates drug target identification.
b. AI enhances the efficiency of molecular screening.
c. AI supports toxicity and efficacy prediction.
d. AI reduces pharmaceutical research time and costs.

Theme 2. Strengthening Precision Medicine Through Multi-Omics Data Integration

The second theme reveals that AI serves as a fundamental enabler of precision medicine. Several studies demonstrated that AI can integrate genomic, proteomic, metabolomic, and clinical data to generate highly personalized treatment recommendations (Fornasier et al., 2024; Alowais et al., 2023; Zhang et al., 2025).

Through its capacity to process and analyze large-scale datasets, AI can identify complex biological patterns that are difficult to detect using conventional statistical methods. This capability facilitates the development of individualized therapies tailored to patients' unique biological characteristics, thereby improving treatment effectiveness while minimizing adverse effects. Consequently, AI contributes not only to pharmaceutical innovation but also to the advancement of patient-centered healthcare systems.

Key Findings:

a. AI supports the development of personalized medicine.
b. Multi-omics integration improves diagnostic and therapeutic accuracy.
c. AI facilitates the identification of relevant biomarkers.
d. AI enhances treatment effectiveness and safety.

Theme 3. Enhancing Sustainability and Resource Efficiency in Pharmaceutical Development

The third theme emphasizes the contribution of AI to sustainability in modern drug development. Several studies reported that predictive models and computational simulations reduce the need for repetitive laboratory experiments, minimize animal testing, and optimize research resource utilization (Wang et al., 2024; Liu et al., 2024; Zhang et al., 2025).

AI also enables pharmaceutical companies to improve manufacturing efficiency, optimize raw material usage, and strengthen quality control through data-driven monitoring systems. These efficiencies contribute not only to reduced operational costs but also to broader sustainability goals within healthcare and pharmaceutical industries.

Key Findings:

a. AI reduces resource waste in pharmaceutical research.
b. AI minimizes dependence on physical experimentation.
c. AI improves pharmaceutical manufacturing efficiency.
d. AI supports sustainability-oriented healthcare innovation.

Theme 4. Transforming Pharmaceutical Innovation Through Generative AI and Advanced Analytics

The fourth theme relates to the emergence of generative AI as a transformative force in pharmaceutical research. The reviewed studies indicate that generative AI can design novel molecular structures that have not previously been discovered through traditional research methods (Liu et al., 2024; Khan et al., 2024).

Beyond generating new compounds, generative AI can optimize molecular characteristics according to predefined therapeutic objectives, including efficacy, safety, and chemical stability. This capability creates substantial opportunities for developing innovative drugs more rapidly and efficiently. As a result, generative AI functions not only as an analytical tool but also as an innovation engine capable of reshaping the future of pharmaceutical development.

Key Findings:

a. Generative AI automatically creates novel molecular structures.
b. AI accelerates lead optimization processes.
c. AI increases the likelihood of successful drug candidates.
d. AI expands innovation capacity in modern pharmaceutical research.

Theme 5. Challenges and Governance of AI Adoption in Drug Development

Despite the significant benefits of AI, the fifth theme highlights several challenges that continue to hinder its widespread adoption. Studies by Ghislat et al. (2024) and Alizadehsani et al. (2023) identified data quality issues, algorithmic bias, limited interoperability, and lack of model transparency as major obstacles to effective AI implementation.

In addition, ethical concerns, patient data privacy, cybersecurity risks, and regulatory compliance remain critical considerations in pharmaceutical and

healthcare applications. Several studies emphasized the importance of Explainable Artificial Intelligence (XAI) in enhancing transparency, trustworthiness, and regulatory acceptance. Therefore, the successful implementation of AI depends not only on technological advancement but also on the establishment of robust governance frameworks, ethical standards, and regulatory policies.

Key Findings:

a. Data quality remains a major challenge.
b. Algorithmic bias may affect prediction accuracy.
c. Explainable AI is essential for transparency and trust.
d. Regulatory and ethical frameworks are critical for AI adoption.

The thematic synthesis demonstrates that the utilization of Artificial Intelligence in sustainable modern precision drug development can be categorized into five interconnected themes. These themes collectively indicate that AI functions as a strategic technology that accelerates drug discovery, strengthens precision medicine, improves sustainability and resource efficiency, drives pharmaceutical innovation through generative AI, and introduces new governance and regulatory challenges. Overall, the findings suggest that AI has evolved from a supporting technology into a central pillar of future pharmaceutical innovation, shaping the next generation of sustainable, efficient, and patient-centered drug development systems.

DISCUSSION

The findings of this systematic literature review demonstrate that Artificial Intelligence (AI) has evolved into a transformative technology that is reshaping the pharmaceutical industry and redefining the future of precision drug development. The thematic synthesis revealed five major dimensions of AI utilization, namely accelerating drug discovery and development, strengthening precision medicine, enhancing sustainability and efficiency, fostering innovation through generative AI, and addressing governance-related challenges. Collectively, these findings suggest that AI is no longer merely a supporting computational tool but has become a strategic enabler that influences every stage of the pharmaceutical value chain.

One of the most significant findings concerns the role of AI in accelerating drug discovery and development processes. Traditional pharmaceutical development is often characterized by lengthy timelines, substantial financial investments, and high failure rates during clinical testing. The reviewed studies consistently indicated that AI-based approaches, particularly machine learning and deep learning, can substantially improve the efficiency of target identification, molecular screening, and lead optimization. These findings are consistent with the broader digital transformation literature, which argues that predictive analytics and computational intelligence can reduce uncertainty and improve decision-making quality in complex scientific environments. By rapidly processing vast amounts of biological and chemical data, AI enables researchers to identify promising therapeutic candidates more effectively than conventional

trial-and-error methods. Consequently, AI contributes to shortening development timelines while simultaneously reducing research expenditures.

The review also highlights the increasingly important role of AI in advancing precision medicine. The integration of genomic, proteomic, metabolomic, and clinical datasets represents one of the most challenging tasks in modern healthcare due to the volume, complexity, and heterogeneity of the data involved. AI offers a powerful solution by enabling the identification of intricate biological patterns that may remain undetected through traditional analytical approaches. The reviewed studies demonstrated that AI-driven precision medicine facilitates the development of individualized treatment strategies tailored to specific patient characteristics. This finding supports the growing shift from population-based therapeutic models toward patient-centered healthcare systems. Personalized treatment approaches not only improve therapeutic effectiveness but also reduce adverse drug reactions, thereby enhancing overall healthcare outcomes. As a result, AI serves as a critical technological foundation for the realization of precision medicine at both clinical and pharmaceutical levels.

Another important contribution identified in this review relates to sustainability in pharmaceutical development. Sustainability has become an increasingly important objective across healthcare systems due to rising research costs, environmental concerns, and resource limitations. The reviewed literature suggests that AI contributes significantly to sustainable pharmaceutical innovation by optimizing resource utilization and reducing unnecessary experimentation. Predictive models and simulation-based approaches allow researchers to evaluate potential drug candidates virtually before conducting costly laboratory studies. This capability minimizes material waste, reduces energy consumption, and decreases reliance on animal testing. Furthermore, AI-driven manufacturing and quality control systems improve production efficiency while maintaining product quality and regulatory compliance. These findings indicate that AI aligns closely with sustainable development objectives by promoting more efficient and responsible pharmaceutical research and production practices.

The emergence of generative AI represents another transformative development identified in the reviewed studies. Unlike conventional AI systems that primarily focus on prediction and classification, generative AI possesses the capability to create entirely new molecular structures with desired therapeutic properties. This innovation marks a significant shift in pharmaceutical research methodologies because it enables the exploration of vast chemical spaces that would be impossible to examine manually. The reviewed studies demonstrated that generative AI can accelerate molecular design and increase the likelihood of discovering viable drug candidates. Such capabilities have the potential to revolutionize pharmaceutical innovation by reducing the time required to generate and optimize novel compounds. Moreover, generative AI may facilitate the development of treatments for rare diseases and complex medical conditions that have historically received limited research attention due to economic or scientific constraints.

Despite these substantial benefits, the review also identified several critical challenges associated with AI adoption in pharmaceutical development. Data quality emerged as one of the most frequently cited concerns. AI models depend heavily on large, accurate, and representative datasets; therefore, incomplete, biased, or inconsistent data can significantly compromise predictive performance. Algorithmic bias presents an additional challenge because biased training data may lead to inequitable outcomes or inaccurate predictions for specific patient populations. These findings highlight the importance of establishing rigorous data governance practices and ensuring dataset diversity throughout the AI development process.

Another challenge concerns the lack of transparency associated with many advanced AI models. Deep learning systems often operate as "black boxes," making it difficult for researchers, clinicians, and regulatory agencies to understand how specific decisions or predictions are generated. This limitation may reduce trust in AI-assisted decision-making and complicate regulatory approval processes. The growing emphasis on Explainable Artificial Intelligence (XAI) reflects the need to enhance model interpretability while maintaining predictive accuracy. Transparent AI systems are particularly important in healthcare and pharmaceutical contexts, where decisions can directly affect patient safety and treatment outcomes.

Regulatory and ethical considerations also constitute major barriers to the widespread implementation of AI in pharmaceutical research. The rapid pace of technological innovation often exceeds the speed at which regulatory frameworks can adapt. As a result, uncertainties remain regarding accountability, validation standards, data privacy, intellectual property rights, and ethical oversight. The reviewed studies suggest that effective governance mechanisms will be essential to ensure that AI technologies are implemented responsibly and consistently across different healthcare and pharmaceutical environments. International collaboration among researchers, industry stakeholders, policymakers, and regulatory agencies may therefore be necessary to establish harmonized standards that support innovation while safeguarding public interests.

The findings further suggest that the future of pharmaceutical innovation will increasingly depend on the convergence of AI, precision medicine, and sustainability principles. Rather than operating as separate domains, these three elements appear to be mutually reinforcing. AI provides the analytical capabilities required to process complex biomedical data, precision medicine offers a patient-centered framework for therapeutic innovation, and sustainability ensures that pharmaceutical advancements remain economically, socially, and environmentally viable. Together, they form a comprehensive model for next-generation drug development that is faster, more effective, and more responsive to evolving healthcare needs.

This review contributes to the existing literature by synthesizing current evidence on the multidimensional role of AI in sustainable precision drug development. Unlike previous studies that primarily focused on technical applications or clinical outcomes, this review integrates technological,

sustainability, and governance perspectives into a unified analytical framework. The findings provide valuable insights for researchers, pharmaceutical companies, healthcare practitioners, and policymakers seeking to maximize the benefits of AI while addressing its associated challenges.

In conclusion, the discussion underscores that Artificial Intelligence has become a central driver of innovation within modern pharmaceutical systems. Its ability to accelerate drug discovery, enhance personalized medicine, improve sustainability, and generate novel therapeutic opportunities positions AI as a foundational technology for the future of healthcare. However, realizing its full potential will require continued efforts to address challenges related to data quality, transparency, ethics, and regulation. By balancing technological advancement with responsible governance, AI can play a pivotal role in creating a more sustainable, efficient, and patient-centered pharmaceutical ecosystem.

CONCLUSION AND RECOMMENDATIONS

This systematic literature review demonstrates that Artificial Intelligence (AI) has become a fundamental technology in optimizing sustainable modern precision drug development. The analysis of ten selected studies identified five major themes: accelerating drug discovery and development processes, strengthening precision medicine through multi-omics data integration, enhancing sustainability and resource efficiency, transforming pharmaceutical innovation through generative AI, and addressing governance and implementation challenges. These findings indicate that AI is no longer merely a supporting computational tool but a strategic driver of innovation throughout the pharmaceutical value chain.

The review highlights that AI contributes significantly to reducing development time and costs, improving therapeutic personalization, increasing research efficiency, and supporting sustainable healthcare objectives. Through predictive analytics, machine learning, deep learning, and generative AI technologies, pharmaceutical organizations can accelerate the identification of promising drug candidates while minimizing resource waste and experimental redundancy. Furthermore, AI enables more patient-centered treatment approaches by integrating complex biological and clinical datasets to support precision medicine.

ADVANCED RESEARCH

Despite these advantages, successful implementation of AI requires addressing challenges related to data quality, algorithmic bias, model transparency, ethical concerns, and regulatory compliance. Therefore, future pharmaceutical innovation should focus on balancing technological advancement with robust governance frameworks. By integrating AI, precision medicine, and sustainability principles, the pharmaceutical industry can develop more effective, efficient, and sustainable healthcare solutions that better respond to evolving global health needs.

REFERENCES

Alizadehsani, R., Oyelere, S. S., Hussain, S., Calixto, R. R., de Albuquerque, V. H. C., Roshanzamir, M., Rahouti, M., & Jagatheesaperumal, S. K. (2023). *Explainable Artificial Intelligence for Drug Discovery and Development: A Comprehensive Survey*. arXiv. https://doi.org/10.48550/arXiv.2309.12177

Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., Aldairem, A., Alrashed, M., Bin Saleh, K., Badreldin, H. A., Al Yami, M. S., Al Harbi, A., Albekairy, A. M., & Alzahrani, T. (2023). Revolutionizing healthcare: The role of artificial intelligence in clinical practice. *BMC Medical Education, 23*(1), 689. https://doi.org/10.1186/s12909-023-04698-z

Chen, J., Wang, Y., & Li, H. (2024). Artificial intelligence and precision medicine: Emerging trends and future directions. *Journal of Personalized Medicine, 14*(3), 245–260.

Fornasier, G., Francescon, S., Baldo, P., & Hossain, M. A. (2024). Drug discovery in the context of precision medicine and artificial intelligence. *Exploration of Drug Science, 2*(3), 42–53.

Ghislat, G., Hernandez-Hernandez, S., Piyawajanusorn, C., & Ballester, P. J. (2024). Data-centric challenges with the application and adoption of artificial intelligence for drug discovery. *Expert Opinion on Drug Discovery, 19*(9), 1023–1034.

Khan, M. K., Raza, M., Shahbaz, M., Hussain, I., Khan, M. F., Xie, Z., Shah, S. S. A., Tareen, A. K., Bashir, Z., & Khan, K. (2024). The recent advances in the approach of artificial intelligence towards drug discovery. *Frontiers in Chemistry, 12*, 1408740. https://doi.org/10.3389/fchem.2024.1408740

Kitchenham, B., & Charters, S. (2007). Guidelines for Performing Systematic Literature Reviews in Software Engineering. EBSE Technical Report.

Liu, Y., Zhang, K., Yang, X., & Wang, Y. (2024). Generative artificial intelligence in drug discovery: Basic framework, recent advances, challenges, and opportunities. *Frontiers in Pharmacology, 15*, 1331062. https://doi.org/10.3389/fphar.2024.1331062

Okoli, C. (2015). A guide to conducting a standalone systematic literature review. Communications of the Association for Information Systems, 37(1), 879–910.

Page, M. J., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71.

Pushkaran, A. C., & Arabi, A. A. (2024). From understanding diseases to drug design: Can artificial intelligence bridge the gap? *Artificial Intelligence Review, 57*(86), 1–35.

Reuters. (2026). Takeda deepens AI drug discovery push with $1.7 billion Iambic deal. Reuters.

Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business Research, 104, 333–339.

The Guardian. (2024). AI used to predict potential new antibiotics in groundbreaking study. The Guardian.

Thomas, J., & Harden, A. (2008). Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Medical Research Methodology, 8(1), 45.

Wang, H., Li, Y., Zhao, Q., & Sun, T. (2024). Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. *European Journal of Pharmaceutical Sciences, 203*, 106938. https://doi.org/10.1016/j.ejps.2024.106938

Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., Li, X., Wu, J. C., & Yang, S. (2025). Artificial intelligence in drug development. *Nature Medicine, 31*(1), 45–59.

Zhang, Y., Mastouri, M., & Zhang, Y. (2024). Accelerating drug discovery, development, and clinical trials by artificial intelligence. *Med, 5*(9), 1050–1070. https://doi.org/10.1016/j.medj.2024.07.005